GlassScriptPhysician profile
Rany A Cherian
NPI 1932126422
$5,763.45
in general payments reported to CMS, 2019-2025
34 companies · $622 in 2025
The $622 reported for 2025 was more than what 83% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $610 · 2021: $674 · 2022: $859 · 2023: $428 · 2024: $1,123 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.16 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,944.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $920.71 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Indivior INC. | $359.06 | 2020-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $278.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.52 | 2022-2024 | Ofev, Jardiance |
| Lilly USA, LLC | $240.23 | 2020-2024 | Mounjaro |
| Braeburn INC. | $236.22 | 2024 | Brixadi |
| Alkermes, INC. | $187.52 | 2019 | |
| Glaxosmithkline, LLC. | $173.39 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $118.22 | 2019 | |
| Amarin Pharma, INC. | $115.29 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $103.05 | 2019 | |
| Merck Sharp & Dohme LLC | $79.55 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $79.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.40 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $66.00 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $64.43 | 2019 | |
| Dexcom, INC. | $45.67 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $45.45 | 2021-2023 | Freestyle Libre 3 |
| Kaleo, INC. | $40.27 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $39.45 | 2019 | |
| Exact Sciences Corporation | $36.58 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $30.01 | 2019 | |
| Astellas Pharma US INC | $29.83 | 2020-2021 | |
| Amryt Pharma Holdings LTD | $27.65 | 2020-2021 | |
| Pear Therapeutics (US), INC. | $26.57 | 2022 | |
| Abbvie INC. | $24.34 | 2021 | |
| Genentech USA, INC. | $20.24 | 2019 | |
| Gilead Sciences, INC. | $18.78 | 2019 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Assertio Therapeutics, INC. | $14.95 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $14.79 | 2025 | |
| Orexo US, INC. | $14.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rany Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.